Sr. Manager, Global Access Strategy & Pricing– Vyndaqel

ROLE SUMMARY

The Global Access Strategy & Pricing (GASP) Manager on Vyndaqel will have major accountability to be the country facing colleague collecting insights as well as developing/disseminating key prioritized strategies/tactics to global markets.    Vyndaqel is facing many upcoming challenges including 18+ contract renegotiation, 2 competitor launches, and loss of exclusivity of the ATTR-hereditary indication in 61mg and Polyneuropathy (PN) indication in 20mg.  In Nov ’26, Vyndaqel Supplemental Protection Certificate (SPC) will expire in some market and generic 61mg products will be launching.   The Vyndaqel GASP manager will work cross-functionally with the team to manage Lifecycle Management (LCM) projects such as LCM strategy/playbook,  LCM masterclass, and negotiation trainings for key markets.  The role will also assist in helping to evolve the Brand Pricing Policy (BPP) as the brand navigates complex challenges over the coming years.   In addition, the role will help to facilitate the GAV Op ’26 process as well as interface with key markets during Op ’26.  The Global Access Strategy & Pricing manager will also help to lead competitive readiness work including developing a Payer Value Proposition, Payer Leave behind/Infographics, as well as helping to develop an overall value narrative vs competition.  Lastly, the manager will also help manage operational brand activities including managing weekly AMT calls, monthly COP meetings, send out weekly VYyndAlert competitive P&MA updates, budget management, management of pricing dashboards such as Access Infinity, and will manage the VYNDACCESS communication platform.

To achieve this, the GASP manager will partner closely with the cross-functional asset teams and run the Access Matrix Team to help evolve the IVAS (Integrate Value & Access Strategy).  The GASP manager will partner with local country access colleagues, and help to review local business cases as appropriate.  Close collaboration and partnership with HTA Value and Evidence colleagues will be essential in order to evolve Vyndaqel’s value narrative, evidence platform, and VBA strategy as it will be a key growth lever in the ’25-27 timframe.  Being proactive, challenging the status quo, and thinking out of the box will be critical for the role. 

About Global Access & Value:   

Global Access & Value (GAV) is a group within Pfizer that brings together experts in health economics and outcomes research, real-world data, patient-centered outcomes assessment, market access, pricing, strategy and contracting. This group is responsible for ensuring patients have affordable, timely access to medicines and vaccines that can help optimize their overall health by generating evidence of value and working with payers and governments around the world to create access. Recognizing challenges with healthcare sustainability and the evolution to value-based care, this group is also exploring innovative approaches and new partnerships to transform the way Pfizer brings medicines and vaccines to market. We recognize our responsibility to be part of the solution and aim to be a leader in the industry.

GAV offers colleagues a distinct opportunity to support evidence-generation and market access strategies across Pfizer’s entire portfolio through all lifecycle stages – from early pipeline to marketed brands to loss of exclusivity and switch to over the counter. Colleagues in GAV have an unparalleled opportunity to grow and develop, while making a meaningful contribution to patient and population health around the world.

ROLE RESPONSIBILITIES

• Understand and communicate Global Payer/HTA insights around renegotiation, competitors and Nov ’26 SPC expiry  
• Evolve the Integrated Value & Access Strategy in response to Competition/LCM challenges
• Lead development of the Payer Value Proposition and 2 Payer Leavebehind for Key markets in IDM/EM + U.S.
• Ensure competitive readiness across key global markets
• Assist team lead in evolving the current Vyndaqel Brand Pricing Policy (BPP) that ensure value for payers, patients, physicians & Pfizer
• Assist team lead in evolving LCM playbook and LCM country readiness training plan
• Lead country workshops for key markets to help evolve renegotiation, competitor and LCM strategy
• Partner with Value & Evidence to identify short term and long-term evidence generation plan to help manage pricing and access risk
• Identify innovative Value Based Agreements to reduce uncertainty in terms of budget impact for payers and update the VBA playbook
• Identify 3 innovative solutions to help manage future pricing and access complexities
• Partner with Pricing dynamics team on IRP impact and LCPA exercises
• Hold monthly COP meetings for 45 markets, review quarterly new